T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy

BACKGROUND: FOLFOX-based adjuvant chemotherapy is a benefit for high-risk stage II and stage III colon cancer after curative resection. But, the prognostic factor or predictive marker for the efficacy of FOLFOX remains unclear. This study was aimed to identify the prognostic value and cumulative imp...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:World J Surg Oncol
Hlavní autoři: An, Min Sung, Yoo, Jong Han, Kim, Kwang Hee, Bae, Ki Beom, Choi, Chang Soo, Hwang, Jin Won, Kim, Ji Hyun, Kim, Bo Mi, Kang, Mi Seon, Oh, Min Kyung, Hong, Kwan Hee
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2015
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4336700/
https://ncbi.nlm.nih.gov/pubmed/25889520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12957-015-0488-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky